Daily Archives: September 20, 2020
[Preprint] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: An international collaborative meta-analysis of randomized trials
20 Sep, 2020 | 21:42h | UTC
Commentary on Twitter
This meta-analysis of 7,913 patients from 26 RCTs (16 unpublished) found no mortality benefit to #hydroxychloroquine or chloroquine in COVID19
Combined summary OR for all-cause mortality for HCQ 1.08, 95%CI 0.99-1.18
Confirms HCQ does not help, may harmhttps://t.co/4o9bXkOo5Q pic.twitter.com/QG1XMzN0da
— Ilan Schwartz is on🦋 (@GermHunterMD) September 19, 2020
Decreased influenza activity during the COVID-19 pandemic
20 Sep, 2020 | 21:39h | UTCCommentary: COVID-19 prevention might translate into – MedicalXpress
Severe COVID-19 infections—knowledge gained and remaining questions
20 Sep, 2020 | 21:43h | UTCSevere COVID-19 Infections—Knowledge Gained and Remaining Questions – JAMA Internal Medicine
Commentary on Twitter
Just out @JAMAInternalMed – our editorial on what we've learned about severe #Covid19 pneumonia so far and what challenges are still ahead. Honored and proud to have written this together with Carolyn Calfee and Dan Brodie. https://t.co/rmVjUWNyvM
— Lieuwe Bos – Acute Pulmonary Medicine (@Acute_Pulmo_Med) September 18, 2020
Transmission of SARS-CoV-2 during long flights
20 Sep, 2020 | 21:36h | UTCRelated Study: In-Flight Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 – CDC Emerging Infectious Diseases
Commentary: Coronavirus can spread on airline flights, two studies show – CNN
Systematic Review: Coronavirus infection in neonates
20 Sep, 2020 | 21:34h | UTCCoronavirus infection in neonates: a systematic review – ADC Fetal & Neonatal
Commentary on Twitter
#SARSCoV2 #review of 26 studies with 44 infected newborns across globe
1. Most aysmptomatic/mild symptoms
2.Most required no RS support
3. Good prognosis-0 deaths
4. 1 in 3 admitted from home
5. Median diagnosis D5; stay 10 days@EBNEO #neoEBM https://t.co/Q0GjmgUg2Y
— Abdul Razak (@DrAbdulRazak_MD) September 19, 2020
A history of herd immunity
20 Sep, 2020 | 21:32h | UTCA history of herd immunity – The Lancet
Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19
20 Sep, 2020 | 21:30h | UTC
A national consensus management pathway for pediatric inflammatory multisystem syndrome temporally associated with COVID-19
20 Sep, 2020 | 21:31h | UTC
Uruguay is winning against Covid-19. This is how
20 Sep, 2020 | 21:27h | UTCUruguay is winning against covid-19. This is how – The BMJ
Commentary on Twitter
Latin America continues to suffer some of the worst tolls of covid-19 but somehow Uruguay has a lid on the pandemic. Its relatively small population made controlling transmission easier but never guaranteed success. @LukeStTaylor looks at how it's happened https://t.co/0k4PlTLQyo
— The BMJ (@bmj_latest) September 20, 2020
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Most homemade masks are doing a great job, even when we sneeze, study finds
20 Sep, 2020 | 21:22h | UTCMost homemade masks are doing a great job, even when we sneeze, study finds – MedicalXpress
Commentary on Twitter
Two layers of T-shirt cloth block droplets with >94% efficiency vs. medical masks, while being ~2x as breathable. Face coverings made from cotton allow washing and reusing, reducing environmental impact of disposable, non-biodegradable facemasks. 😷👕😷 https://t.co/kyqB4XoZMl
— peter kilmarx (@PeterKilmarx) August 26, 2020
Who gets a COVID vaccine first? Access plans are taking shape
20 Sep, 2020 | 21:24h | UTCWho gets a COVID vaccine first? Access plans are taking shape – Nature
Related: WHO Guidance: Allocation and prioritization of COVID-19 vaccination
Commentary on Twitter
Advisory groups around the world are working out plans for who should get priority access to a #covid19 vaccine: https://t.co/9g67rFJUrT pic.twitter.com/BLhAcKiVCK
— nature (@Nature) September 18, 2020
Hangover from alcohol boom could last long after pandemic ends
20 Sep, 2020 | 21:18h | UTCHangover From Alcohol Boom Could Last Long After Pandemic Ends – NPR
Commentary on Twitter
The alcohol industry has thrived during the #pandemic. But alcohol-related illnesses kill 88,000+ Americans every year—and the skyrocketing sales suggest a worrying reliance on alcohol to ease a stressful situation. https://t.co/8GIbAi9dM7
— Global Health NOW (@ghn_news) September 20, 2020
Systematic review: Therapies for clinically localized prostate cancer
20 Sep, 2020 | 21:15h | UTCTherapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality
Final report: Therapies for Clinically Localized Prostate Cancer AND Evidence Summary
Perspective: How we survive the winter
20 Sep, 2020 | 21:21h | UTCHow We Survive the Winter – The Atlantic
The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion
20 Sep, 2020 | 21:16h | UTC
Commentary on Twitter
Non-communicable diseases & injuries (NCDI) cause more death & disability at every age among the world’s poorest billion than in wealthy countries— new @ncdipoverty Commission provides cost-effective & equitable interventions to address #NCDIPoverty https://t.co/MPunOR7fws pic.twitter.com/IrGj2obZXx
— The Lancet (@TheLancet) September 14, 2020
[Abstract Only] Survival with Olaparib in metastatic castration-resistant prostate cancer
20 Sep, 2020 | 21:13h | UTC
Commentary on Twitter
The PROfound trial showed that olaparib prolonged imaging-based progression-free survival among patients whose tumors contained defects in the BRCA1, BRCA2, or ATM. With longer follow-up, the trial now shows that olaparib prolonged overall survival in these patients. #ESMO20
— NEJM (@NEJM) September 20, 2020
[Abstract Only] Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
20 Sep, 2020 | 21:11h | UTC
Commentary on Twitter
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. #ESMO20
— NEJM (@NEJM) September 18, 2020